Will GSK-Hanmi Deal Trigger Similar Tie-ups With Korean Pharmas?
This article was originally published in PharmAsia News
Executive Summary
Korea’s Hanmi Pharmaceutical is positioning itself as a partner of choice for reformulations and fixed-dose combinations after inking its second major deal with a multinational.